Free Trial
→ URGENT: Someone's Moving Gold Out of London... (From Golden Portfolio) (Ad) Buy SBRA Stock  Free SBRA Stock Alerts

Sabra Health Care REIT (SBRA) Financials

Sabra Health Care REIT logo
$17.49 +0.07 (+0.40%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$17.52 +0.04 (+0.20%)
As of 05/30/2025 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Sabra Health Care REIT

Annual Income Statements for Sabra Health Care REIT

This table shows Sabra Health Care REIT's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Income / (Loss) Attributable to Common Shareholders		 127 14 -78 -113 138 69 269 148 60 69
Consolidated Net Income / (Loss)		 127 14 -78 -113 138 69 279 158 70 79
Net Income / (Loss) Continuing Operations		 127 17 20 -113 138 69 279 158 70 79
Total Pre-Tax Income 		128 19 22 81 156 79 288 159 71 80
Total Revenue		 591 536 518 437 586 647 625 320 265 241
Net Interest Income / (Expense)		 -115 -113 -105 -99 0.00 0.00 0.00 -88 0.00 0.00
Total Interest Income		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Interest Expense		 115 113 105 99 0.00 0.00 0.00 88 0.00 0.00
Long-Term Debt Interest Expense		 115 113 105 99 - - - 88 - -
Total Non-Interest Income		 706 649 623 535 586 647 625 408 265 241
Service Charges on Deposit Accounts		 285 236 187 156 156 - - 26 7.79 3.51
Other Service Charges		 40 38 36 18 14 212 91 18 38 28
Net Realized & Unrealized Capital Gains on Investments		 0.00 -1.54 -0.41 -35 -14 -16 -2.92 -0.55 -6.68 -0.16
Other Non-Interest Income		 381 376 401 397 431 452 537 364 225 210
Provision for Credit Losses		 -0.57 0.19 0.14 3.94 - - - - - -
Total Non-Interest Expense		 465 440 484 556 447 571 466 213 193 161
Other Operating Expenses		 50 47 40 35 33 31 37 32 18 16
Depreciation Expense		 170 183 188 179 177 182 191 114 68 63
Impairment Charge		 18 14 94 9.50 4.00 122 1.41 1.33 30 0.00
Other Special Charges		 227 195 163 333 234 236 236 35 76 75
Nonoperating Income / (Expense), net		 2.10 -77 -12 12 - 2.30 128 52 - -
Income Tax Expense		 1.01 2.00 1.24 1.85 0.71 3.40 3.01 0.65 1.05 0.75
Other Adjustments to Consolidated Net Income / (Loss)		 -0.40 -2.90 -98 - - - - - - -
Basic Earnings per Share		 $0.54 $0.06 ($0.34) ($0.52) $0.67 $0.37 $1.51 $1.40 $0.92 $1.11
Weighted Average Basic Shares Outstanding		 233.50M 231.20M 230.95M 219.07M 206.22M 187.17M 178.31M 105.62M 65.28M 62.24M
Diluted Earnings per Share		 $0.54 $0.06 ($0.34) ($0.52) $0.67 $0.37 $1.51 $1.40 $0.92 $1.11
Weighted Average Diluted Shares Outstanding		 236.05M 232.79M 230.95M 219.07M 207.25M 188.13M 178.72M 105.84M 65.52M 62.46M
Weighted Average Basic & Diluted Shares Outstanding		 237.91M 231.48M 231.16M 230.90M 210.72M 205.27M 178.40M 105.80M 65.30M 62.30M
Cash Dividends to Common per Share		 $1.20 $1.20 $1.20 $1.20 $1.35 $1.80 $1.80 $1.73 $1.67 $1.60

Quarterly Income Statements for Sabra Health Care REIT

This table shows Sabra Health Care REIT's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 40 47 30 24 26 17 -15 21 -9.49 -85 -50
Consolidated Net Income / (Loss)		 40 47 30 24 26 17 -15 21 -9.49 -85 -50
Net Income / (Loss) Continuing Operations		 40 47 30 24 26 19 -14 22 -9.49 13 -50
Total Pre-Tax Income 		40 47 29 24 27 18 -14 22 -7.92 3.49 -45
Total Revenue		 156 156 149 147 139 135 136 133 132 137 115
Net Interest Income / (Expense)		 -27 -28 -29 -29 -28 -28 -28 -28 -29 -28 -27
Total Interest Income		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Interest Expense		 27 28 29 29 28 28 28 28 29 28 27
Long-Term Debt Interest Expense		 27 28 29 29 28 28 28 28 29 28 27
Total Non-Interest Income		 184 184 178 176 168 163 164 161 160 165 142
Service Charges on Deposit Accounts		 77 77 74 68 66 61 60 58 57 53 48
Other Service Charges		 10 11 9.70 9.18 9.70 9.13 11 8.46 9.07 8.97 9.93
Other Non-Interest Income		 96 96 95 99 92 93 93 94 96 103 84
Provision for Credit Losses		 -0.17 -0.13 -0.15 -0.16 -0.14 -0.36 0.33 0.43 -0.21 0.15 -0.22
Total Non-Interest Expense		 116 115 114 125 113 116 103 102 119 116 164
Other Operating Expenses		 13 13 12 13 12 17 11 9.53 11 11 9.68
Depreciation Expense		 43 42 43 42 43 43 43 44 53 50 47
Impairment Charge		 0.00 - 0.00 15 3.14 7.27 0.00 0.00 7.06 21 61
Other Special Charges		 60 59 59 55 55 49 49 49 49 34 46
Income Tax Expense		 0.41 0.38 -0.27 0.44 0.45 0.49 0.46 0.33 0.73 0.12 0.58
Other Adjustments to Consolidated Net Income / (Loss)		 0.22 - 0.21 0.08 - - -0.65 -0.65 - - -
Basic Earnings per Share		 $0.17 $0.20 $0.13 $0.10 $0.11 $0.08 ($0.07) $0.09 ($0.04) ($0.37) ($0.22)
Weighted Average Basic Shares Outstanding		 237.89M 233.50M 234.29M 231.62M 231.45M 231.20M 231.22M 231.20M 231.16M 230.95M 230.98M
Diluted Earnings per Share		 $0.17 $0.20 $0.13 $0.10 $0.11 $0.08 ($0.07) $0.09 ($0.04) ($0.37) ($0.22)
Weighted Average Diluted Shares Outstanding		 240.30M 236.05M 237.04M 233.75M 233.37M 232.79M 231.22M 232.24M 231.16M 230.95M 230.98M
Weighted Average Basic & Diluted Shares Outstanding		 237.94M 237.91M 236.59M 234.26M 231.50M 231.48M 231.22M 231.22M 231.20M 231.16M 230.98M
Cash Dividends to Common per Share		 $0.30 - $0.30 $0.30 $0.30 - $0.30 $0.30 $0.30 - $0.30

Annual Cash Flow Statements for Sabra Health Care REIT

This table details how cash moves in and out of Sabra Health Care REIT's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Change in Cash & Equivalents		 20 -6.60 -62 50 16 -11 -527 552 17 -54
Net Cash From Operating Activities		 311 301 316 356 355 372 361 136 176 121
Net Cash From Continuing Operating Activities		 311 301 316 356 355 372 361 136 176 121
Net Income / (Loss) Continuing Operations		 127 14 -78 -113 138 69 279 158 70 79
Consolidated Net Income / (Loss)		 127 14 -78 -113 138 69 279 158 70 79
Provision For Loan Losses		 -0.57 0.19 0.14 3.94 1.86 1.24 39 17 5.54 13
Depreciation Expense		 170 183 188 179 177 182 191 114 68 63
Amortization Expense		 10 12 11 8.37 8.42 10 10 7.78 5.68 5.28
Non-Cash Adjustments to Reconcile Net Income		 27 94 214 256 32 134 -141 -73 21 -20
Changes in Operating Assets and Liabilities, net		 -23 -2.73 -20 23 -2.74 -24 -18 -88 4.97 -20
Net Cash From Investing Activities		 -109 103 -216 -336 -136 263 -258 -183 142 -489
Net Cash From Continuing Investing Activities		 -109 103 -216 -336 -136 263 -258 -183 142 -489
Purchase of Property, Leasehold Improvements and Equipment		 -55 -85 -54 -43 -47 -25 -28 -6.95 -1.00 -3.69
Purchase of Investment Securities		 -156 -106 -267 -397 -111 -64 -672 -440 -171 -524
Sale and/or Maturity of Investments		 102 289 101 104 22 347 434 183 314 33
Other Investing Activities, net		 0.00 5.46 4.60 0.00 0.00 5.08 6.87 3.76 - -
Net Cash From Financing Activities		 -182 -410 -162 30 -202 -646 -629 599 -301 314
Net Cash From Continuing Financing Activities		 -182 -410 -162 30 -202 -646 -629 599 -300 314
Issuance of Debt		 0.00 -92 204 792 0.00 639 0.00 434 69 289
Repayment of Debt		 13 -1.98 -81 -798 -3.07 -1,483 -159 -4.15 -244 -3.13
Repurchase of Common Equity		 86 - - - 80 - -0.50 - - -
Payment of Dividends		 -280 -277 -277 -263 -278 -335 -325 -182 -119 -110
Other Financing Activities, Net		 -0.09 -36 -2.52 -9.32 -0.83 -16 -0.49 351 -5.94 -1.27
Cash Interest Paid		 105 102 98 85 93 124 138 70 59 54
Cash Income Taxes Paid		 1.39 1.67 1.66 1.84 2.44 3.91 1.80 0.71 0.85 0.66

Quarterly Cash Flow Statements for Sabra Health Care REIT

This table details how cash moves in and out of Sabra Health Care REIT's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 -37 -2.44 27 -24 19 7.60 6.75 -6.34 -15 23 -40
Net Cash From Operating Activities		 80 80 98 80 53 79 83 70 68 68 108
Net Cash From Continuing Operating Activities		 80 80 98 80 53 79 83 70 68 68 108
Net Income / (Loss) Continuing Operations		 40 47 30 24 26 17 -15 21 -9.49 -85 -50
Consolidated Net Income / (Loss)		 40 47 30 24 26 17 -15 21 -9.49 -85 -50
Provision For Loan Losses		 -0.17 -0.13 -0.15 -0.16 -0.14 -0.36 0.33 0.43 -0.21 0.15 -0.22
Depreciation Expense		 43 42 43 42 43 43 43 44 53 50 47
Amortization Expense		 1.73 1.73 2.61 3.07 3.07 3.09 3.09 3.08 3.01 2.79 2.80
Non-Cash Adjustments to Reconcile Net Income		 2.44 -3.89 8.79 14 8.33 11 45 7.17 31 116 80
Changes in Operating Assets and Liabilities, net		 -7.53 -6.75 14 -2.05 -28 4.91 6.65 -5.68 -8.62 -16 28
Net Cash From Investing Activities		 -16 19 -57 -57 -13 -62 60 -8.19 113 -31 -57
Net Cash From Continuing Investing Activities		 -16 19 -57 -57 -13 -62 60 -8.19 113 -31 -57
Purchase of Property, Leasehold Improvements and Equipment		 -7.78 -16 -14 -12 -13 -21 -26 -18 -20 -21 -14
Purchase of Investment Securities		 -11 -19 -80 -56 -1.30 -41 -0.90 -12 -53 -49 -65
Sale and/or Maturity of Investments		 1.13 59 36 6.96 0.39 -0.20 86 19 184 33 23
Other Investing Activities, net		 0.81 -5.32 0.60 4.11 0.62 0.63 0.70 2.70 1.43 5.43 -1.33
Net Cash From Financing Activities		 -101 -101 -14 -46 -20 -9.36 -136 -68 -196 -14 -92
Net Cash From Continuing Financing Activities		 -101 -101 -14 -46 -20 -9.36 -136 -68 -196 -14 -92
Issuance of Debt		 -24 -59 22 -15 52 61 -66 20 -106 204 -142
Issuance of Common Equity		 -5.39 - 35 39 -2.61 -0.49 -0.04 -0.31 -1.85 - -
Repayment of Debt		 -0.52 14 -0.51 -0.51 -0.50 -0.50 -0.50 -0.49 -0.49 -148 123
Payment of Dividends		 -71 -71 -70 -69 -69 -69 -69 -69 -69 -69 -69
Other Financing Activities, Net		 -0.08 -0.01 - - -0.08 -0.01 -0.01 -18 -18 -0.01 -2.50
Cash Interest Paid		 20 34 21 30 20 29 20 30 22 29 19

Annual Balance Sheets for Sabra Health Care REIT

This table presents Sabra Health Care REIT's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Total Assets		 5,304 5,386 5,748 5,967 5,986 6,069 6,665 7,032 2,266 2,469
Cash and Due from Banks		 60 41 49 112 59 39 50 519 26 7.43
Restricted Cash		 5.87 5.43 4.62 3.89 6.45 10 9.43 69 9.00 9.81
Trading Account Securities		 122 137 135 97 289 319 340 0.00 - -
Loans and Leases, Net of Allowance		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Premises and Equipment, Net		 4,514 4,617 4,959 5,163 5,285 5,341 5,854 5,994 2,010 2,040
Intangible Assets		 27 31 40 54 83 102 131 167 26 -
Other Assets		 574 554 559 537 263 258 281 283 195 300
Total Liabilities & Shareholders' Equity		 5,304 5,386 5,748 5,967 5,986 6,069 6,665 7,032 2,266 2,469
Total Liabilities		 2,562 2,584 2,691 2,587 2,576 2,581 3,411 3,595 1,250 1,415
Short-Term Debt		 107 94 197 0.00 - - 624 641 26 255
Other Short-Term Payables		 118 137 142 143 146 - 95 103 40 35
Long-Term Debt		 2,311 2,320 2,310 2,394 2,372 2,402 2,608 2,753 1,185 1,125
Other Long-Term Liabilities		 27 33 42 50 58 179 84 98 0.00 -
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 2,741 2,803 3,056 3,380 3,409 3,488 3,255 3,437 1,016 1,054
Total Preferred & Common Equity		 2,741 2,803 3,056 3,380 3,409 3,488 3,250 3,433 1,016 1,054
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.06 0.06 0.06
Total Common Equity		 2,741 2,803 3,056 3,380 3,409 3,488 3,250 3,433 1,016 1,054
Common Stock		 4,595 4,497 4,489 4,485 4,165 4,074 3,510 3,639 1,210 1,203
Accumulated Other Comprehensive Income / (Loss)		 21 24 19 -10 -40 -12 12 11 -1.80 -7.33
Other Equity Adjustments		 -1,875 -1,718 -1,452 -1,095 -716 -573 -272 -217 -192 -142

Quarterly Balance Sheets for Sabra Health Care REIT

This table presents Sabra Health Care REIT's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 5,233 5,366 5,351 5,374 5,381 5,524 5,556 5,845
Cash and Due from Banks		 23 63 36 60 33 27 34 26
Restricted Cash		 6.24 5.97 5.91 6.00 5.60 5.15 5.15 4.86
Trading Account Securities		 121 131 130 132 136 140 139 208
Loans and Leases, Net of Allowance		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Premises and Equipment, Net		 4,488 4,574 4,566 4,577 4,603 4,752 4,797 5,019
Intangible Assets		 25 29 28 28 33 36 39 48
Other Assets		 571 563 585 571 570 564 542 539
Total Liabilities & Shareholders' Equity		 5,233 5,366 5,351 5,374 5,381 5,524 5,556 5,845
Total Liabilities		 2,531 2,621 2,589 2,607 2,512 2,581 2,580 2,636
Short-Term Debt		 83 153 130 146 33 101 80 139
Other Short-Term Payables		 112 123 113 113 128 122 143 145
Long-Term Debt		 2,311 2,318 2,316 2,317 2,317 2,320 2,317 2,308
Other Long-Term Liabilities		 25 28 30 31 34 39 40 44
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 2,702 2,745 2,762 2,767 2,869 2,944 2,976 3,209
Total Preferred & Common Equity		 2,702 2,745 2,762 2,767 2,869 2,944 2,976 3,209
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 2,702 2,745 2,762 2,767 2,869 2,944 2,976 3,209
Common Stock		 4,594 4,577 4,539 4,498 4,494 4,491 4,490 4,487
Accumulated Other Comprehensive Income / (Loss)		 15 17 31 31 40 32 17 19
Other Equity Adjustments		 -1,907 -1,849 -1,808 -1,762 -1,665 -1,580 -1,531 -1,297

Annual Metrics And Ratios for Sabra Health Care REIT

This table displays calculated financial ratios and metrics derived from Sabra Health Care REIT's official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 10.29% 3.43% 18.59% -25.54% -9.43% 3.60% 95.41% 20.91% 9.78% 44.69%
EBITDA Growth		 5.33% 24.97% 265.38% -80.37% 20.76% -25.59% 57.83% 57.28% -2.10% 57.51%
EBIT Growth		 32.26% 182.90% 127.22% -188.92% 80.88% -51.73% 48.95% 50.21% -11.12% 70.82%
NOPAT Growth		 47.00% 167.89% -52.47% -56.90% 110.58% -53.32% 48.00% 51.77% -11.56% 69.23%
Net Income Growth		 821.14% 117.73% 31.48% -181.82% 100.55% -75.27% 76.23% 125.60% -11.56% 69.23%
EPS Growth		 800.00% 117.65% 34.62% -177.61% 81.08% -75.50% 7.86% 52.17% -17.12% 42.31%
Operating Cash Flow Growth		 3.32% -4.80% -11.41% 0.43% -4.73% 3.30% 165.55% -22.82% 45.27% 41.91%
Free Cash Flow Firm Growth		 -57.66% 77.91% 226.05% -71.81% -60.59% 33.25% 111.17% -1,720.76% 186.43% 61.53%
Invested Capital Growth		 -1.11% -6.23% -3.65% -0.13% -1.85% -9.19% -5.05% 206.87% -8.52% 19.70%
Revenue Q/Q Growth		 3.63% -0.30% 19.48% -26.99% 5.66% 41.16% -11.30% 4.06% -3.00% -5.22%
EBITDA Q/Q Growth		 8.01% 45.30% 38.10% -73.67% 41.24% 229.83% -36.16% 41.93% -3.20% 3.67%
EBIT Q/Q Growth		 24.28% 4,650.14% 230.46% -319.46% 214.64% 169.66% -55.34% 44.86% -5.74% 1.88%
NOPAT Q/Q Growth		 21.53% 73.49% 2,248.50% -72.43% 256.24% 324.67% -61.17% 37.37% -2.65% 0.93%
Net Income Q/Q Growth		 30.40% 115.57% -356.23% -336.92% 233.92% 597.57% -30.65% 104.19% -2.65% 3.72%
EPS Q/Q Growth		 28.57% 115.38% -277.78% -136.36% -6.94% 1,133.33% -36.82% 47.37% -3.16% -7.50%
Operating Cash Flow Q/Q Growth		 0.40% 3.85% -8.77% 2.45% -1.69% 5.06% -1.36% 42.38% 0.07% 29.92%
Free Cash Flow Firm Q/Q Growth		 72.12% -11.26% -35.14% 4,915.69% 86.27% -22.80% 957.74% -9.77% 3.13% 12.55%
Invested Capital Q/Q Growth		 -1.08% -0.03% -1.64% -4.26% -0.10% 0.09% -3.70% 7.13% 1.14% 1.47%
Profitability Metrics		 - - - - - - - - - -
EBITDA Margin		 51.82% 54.26% 44.91% 14.58% 55.30% 41.47% 57.74% 71.49% 54.96% 61.62%
EBIT Margin		 21.33% 17.79% 6.50% -28.33% 23.72% 11.88% 25.50% 33.45% 26.93% 33.25%
Profit (Net Income) Margin		 21.45% 2.57% -14.99% -25.94% 23.60% 10.66% 44.66% 49.52% 26.54% 32.94%
Tax Burden Percent		 98.91% 73.74% -358.14% -140.39% 88.89% 87.13% 97.06% 99.60% 98.53% 99.07%
Interest Burden Percent		 101.66% 19.58% 64.34% -65.21% 111.93% 102.99% 180.45% 148.63% 100.04% 100.00%
Effective Tax Rate		 0.78% 10.73% 5.73% 2.29% 0.46% 4.29% 1.05% 0.41% 1.47% 0.93%
Return on Invested Capital (ROIC)		 2.41% 1.58% 0.56% 1.16% 2.66% 1.19% 2.37% 2.35% 3.01% 3.55%
ROIC Less NNEP Spread (ROIC-NNEP)		 2.48% -1.32% -3.90% -6.40% 1.96% 1.03% 6.03% 4.60% 3.01% 3.55%
Return on Net Nonoperating Assets (RNNOA)		 2.16% -1.11% -2.97% -4.49% 1.36% 0.86% 5.97% 4.76% 3.77% 4.40%
Return on Equity (ROE)		 4.57% 0.47% -2.41% -3.34% 4.01% 2.05% 8.34% 7.11% 6.78% 7.96%
Cash Return on Invested Capital (CROIC)		 3.52% 8.01% 4.28% 1.29% 4.52% 10.82% 7.55% -99.34% 11.91% -14.38%
Operating Return on Assets (OROA)		 2.36% 1.71% 0.58% -2.07% 2.31% 1.21% 2.33% 2.30% 3.01% 3.53%
Return on Assets (ROA)		 2.37% 0.25% -1.33% -1.90% 2.30% 1.08% 4.08% 3.41% 2.97% 3.50%
Return on Common Equity (ROCE)		 4.57% 0.47% -2.41% -3.34% 4.01% 2.05% 8.33% 7.11% 6.78% 7.95%
Return on Equity Simple (ROE_SIMPLE)		 4.62% 0.49% -2.54% -3.35% 4.06% 1.98% 8.59% 4.61% 6.91% 7.53%
Net Operating Profit after Tax (NOPAT)		 125 85 32 67 155 74 158 107 70 79
NOPAT Margin		 21.17% 15.88% 6.13% 15.30% 26.43% 11.37% 25.23% 33.31% 26.54% 32.94%
Net Nonoperating Expense Percent (NNEP)		 -0.07% 2.90% 4.46% 7.55% 0.70% 0.16% -3.66% -2.25% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 78.76% 82.18% 93.47% 127.43% 76.28% 88.12% 74.50% 66.55% 73.07% 66.75%
Earnings before Interest and Taxes (EBIT)		 126 95 34 -124 139 77 159 107 71 80
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 306 291 233 64 324 269 361 229 145 148
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 1.47 1.07 0.78 0.72 0.77 0.79 0.55 0.54 0.81 0.59
Price to Tangible Book Value (P/TBV)		 1.48 1.08 0.79 0.73 0.79 0.81 0.58 0.57 0.83 0.59
Price to Revenue (P/Rev)		 6.81 5.60 4.58 5.54 4.46 4.26 2.88 5.84 3.10 2.59
Price to Earnings (P/E)		 31.76 217.85 0.00 0.00 18.88 39.98 6.68 12.61 13.65 9.01
Dividend Yield		 7.06% 9.26% 11.69% 11.33% 10.69% 12.64% 17.84% 12.21% 13.30% 16.72%
Earnings Yield		 3.15% 0.46% 0.00% 0.00% 5.30% 2.50% 14.97% 7.93% 7.33% 11.10%
Enterprise Value to Invested Capital (EV/IC)		 1.24 1.03 0.87 0.81 0.85 0.87 0.77 0.69 0.90 0.82
Enterprise Value to Revenue (EV/Rev)		 10.79 10.02 9.32 10.76 8.39 7.89 7.96 14.63 7.54 8.24
Enterprise Value to EBITDA (EV/EBITDA)		 20.83 18.46 20.74 73.84 15.17 19.03 13.79 20.47 13.73 13.37
Enterprise Value to EBIT (EV/EBIT)		 50.59 56.30 143.23 0.00 35.36 66.46 31.22 43.74 28.02 24.78
Enterprise Value to NOPAT (EV/NOPAT)		 50.99 63.07 151.93 70.35 31.74 69.44 31.55 43.92 28.42 25.02
Enterprise Value to Operating Cash Flow (EV/OCF)		 20.53 17.85 15.28 13.19 13.87 13.72 13.80 34.46 11.34 16.40
Enterprise Value to Free Cash Flow (EV/FCFF)		 34.89 12.43 19.89 63.17 18.64 7.63 9.90 0.00 7.19 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.88 0.86 0.82 0.71 0.70 0.69 0.99 0.99 1.19 1.31
Long-Term Debt to Equity		 0.84 0.83 0.76 0.71 0.70 0.69 0.80 0.80 1.17 1.07
Financial Leverage		 0.87 0.84 0.76 0.70 0.69 0.84 0.99 1.03 1.25 1.24
Leverage Ratio		 1.93 1.90 1.82 1.76 1.75 1.89 2.05 2.09 2.29 2.27
Compound Leverage Factor		 1.96 0.37 1.17 -1.15 1.96 1.95 3.69 3.10 2.29 2.27
Debt to Total Capital		 46.86% 46.28% 45.06% 41.47% 41.03% 40.78% 49.82% 49.69% 54.38% 56.70%
Short-Term Debt to Total Capital		 2.07% 1.81% 3.54% 0.00% 0.00% 0.00% 9.62% 9.38% 1.17% 10.48%
Long-Term Debt to Total Capital		 44.80% 44.47% 41.52% 41.47% 41.03% 40.78% 40.21% 40.30% 53.21% 46.22%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.07% 0.07% 0.00% 0.00%
Common Equity to Total Capital		 53.14% 53.72% 54.94% 58.53% 58.97% 59.22% 50.11% 50.25% 45.61% 43.30%
Debt to EBITDA		 7.90 8.31 10.78 37.62 7.32 8.94 8.96 14.85 8.33 9.29
Net Debt to EBITDA		 7.68 8.15 10.55 35.80 7.11 8.76 8.79 12.28 8.09 9.18
Long-Term Debt to EBITDA		 7.55 7.98 9.93 37.62 7.32 8.94 7.23 12.04 8.15 7.57
Debt to NOPAT		 19.34 28.38 78.95 35.84 15.30 32.63 20.50 31.86 17.24 17.38
Net Debt to NOPAT		 18.81 27.83 77.26 34.11 14.88 31.96 20.12 26.35 16.75 17.16
Long-Term Debt to NOPAT		 18.48 27.27 72.75 35.84 15.30 32.63 16.54 25.84 16.87 14.17
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.06% 0.13% 0.10% 0.01% 0.01%
Liquidity Ratios		 - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 183 432 243 74 264 670 503 -4,499 278 -321
Operating Cash Flow to CapEx		 567.59% 354.22% 579.61% 835.60% 749.36% 1,463.50% 1,301.90% 1,952.67% 17,540.18% 3,282.76%
Free Cash Flow to Firm to Interest Expense		 1.59 3.82 2.30 0.75 0.00 0.00 0.00 -50.87 0.00 0.00
Operating Cash Flow to Interest Expense		 2.69 2.66 2.99 3.61 0.00 0.00 0.00 1.54 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 2.22 1.91 2.48 3.18 0.00 0.00 0.00 1.46 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.11 0.10 0.09 0.07 0.10 0.10 0.09 0.07 0.11 0.11
Fixed Asset Turnover		 0.13 0.11 0.10 0.08 0.11 0.12 0.11 0.08 0.13 0.13
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 5,159 5,217 5,563 5,774 5,782 5,891 6,487 6,832 2,226 2,434
Invested Capital Turnover		 0.11 0.10 0.09 0.08 0.10 0.10 0.09 0.07 0.11 0.11
Increase / (Decrease) in Invested Capital		 -58 -347 -211 -7.60 -109 -596 -345 4,605 -207 401
Enterprise Value (EV)		 6,375 5,364 4,824 4,700 4,920 5,112 4,976 4,680 1,995 1,986
Market Capitalization		 4,024 2,997 2,371 2,421 2,613 2,759 1,799 1,868 819 623
Book Value per Share		 $11.59 $12.12 $13.23 $14.78 $16.48 $18.01 $18.23 $19.26 $15.56 $16.18
Tangible Book Value per Share		 $11.47 $11.99 $13.06 $14.54 $16.08 $17.49 $17.50 $18.32 $15.16 $16.18
Total Capital		 5,159 5,217 5,563 5,774 5,782 5,891 6,487 6,832 2,226 2,434
Total Debt		 2,418 2,414 2,507 2,394 2,372 2,402 3,232 3,394 1,211 1,380
Total Long-Term Debt		 2,311 2,320 2,310 2,394 2,372 2,402 2,608 2,753 1,185 1,125
Net Debt		 2,351 2,367 2,453 2,279 2,307 2,353 3,172 2,807 1,176 1,363
Capital Expenditures (CapEx)		 55 85 54 43 47 25 28 6.95 1.00 3.69
Net Nonoperating Expense (NNE)		 -1.68 71 109 180 17 4.59 -121 -52 0.00 0.00
Net Nonoperating Obligations (NNO)		 2,418 2,414 2,507 2,394 2,372 2,402 3,232 3,394 1,211 1,380
Total Depreciation and Amortization (D&A)		 180 195 199 187 185 192 202 122 74 68
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.54 $0.06 ($0.34) ($0.52) $0.00 $0.37 $1.51 $1.40 $0.92 $1.11
Adjusted Weighted Average Basic Shares Outstanding		 233.50M 231.20M 230.95M 219.07M 0.00 187.17M 178.31M 105.62M 65.28M 62.24M
Adjusted Diluted Earnings per Share		 $0.54 $0.06 ($0.34) ($0.52) $0.00 $0.37 $1.51 $1.40 $0.92 $1.11
Adjusted Weighted Average Diluted Shares Outstanding		 236.05M 232.79M 230.95M 219.07M 0.00 188.13M 178.72M 105.84M 65.52M 62.46M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.37 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 237.91M 231.48M 231.16M 230.90M 0.00 205.27M 178.32M 178.26M 65.29M 65.19M
Normalized Net Operating Profit after Tax (NOPAT)		 369 272 274 402 392 416 392 173 176 160
Normalized NOPAT Margin		 62.41% 50.81% 52.85% 92.00% 66.80% 64.31% 62.78% 54.04% 66.45% 66.52%
Pre Tax Income Margin		 21.69% 3.48% 4.18% 18.47% 26.55% 12.23% 46.01% 49.72% 26.94% 33.25%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 1.09 0.84 0.32 -1.25 0.00 0.00 0.00 1.21 0.00 0.00
NOPAT to Interest Expense		 1.08 0.75 0.30 0.68 0.00 0.00 0.00 1.20 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.62 0.09 -0.20 -1.69 0.00 0.00 0.00 1.13 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.61 0.00 -0.22 0.24 0.00 0.00 0.00 1.13 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 221.09% 2,016.92% -357.14% -232.15% 201.06% 486.01% 116.52% 114.97% 169.88% 138.44%
Augmented Payout Ratio		 153.13% 2,016.92% -357.14% -232.15% 143.20% 486.01% 116.70% 114.97% 169.88% 138.44%

Quarterly Metrics And Ratios for Sabra Health Care REIT

This table displays calculated financial ratios and metrics derived from Sabra Health Care REIT's official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 12.50% 15.26% 9.46% 10.59% 5.71% -1.17% 18.47% 3.57% -4.60% 160.32% 10.45%
EBITDA Growth		 16.97% 30.02% 1.92% -12.84% 5.97% -10.11% 9,518.78% 11.05% -22.79% 696.43% -98.55%
EBIT Growth		 48.34% 108.72% 7.71% -24.81% 109.37% -3.19% 165.87% 39.14% -68.80% 153.13% -611.44%
NOPAT Growth		 49.30% 118.88% 55.27% -25.06% 182.15% 76.83% 172.29% 24.32% -78.08% 161.07% -331.89%
Net Income Growth		 53.52% 172.18% 297.26% 13.15% 376.74% 120.20% 69.84% 26.08% -123.37% -248.82% -589.72%
EPS Growth		 54.55% 150.00% 285.71% 11.11% 375.00% 121.62% 68.18% 28.57% -122.22% -208.33% -540.00%
Operating Cash Flow Growth		 52.03% 1.56% 17.35% 13.93% -22.69% 16.50% -23.28% -8.15% 8.20% -30.99% 2.14%
Free Cash Flow Firm Growth		 3.18% -73.03% -91.60% -61.76% -52.45% 64.95% 33.76% 471.59% 225.36% 2,393.27% 249.39%
Invested Capital Growth		 -2.57% -1.11% -0.06% -2.89% -2.65% -6.23% -7.73% -7.49% -6.05% -3.65% -6.23%
Revenue Q/Q Growth		 0.21% 5.13% 1.11% 5.61% 2.67% -0.16% 2.15% 0.95% -4.02% 19.68% -10.69%
EBITDA Q/Q Growth		 -0.02% 6.66% 19.43% -7.41% 14.13% -16.40% 2.14% 12.57% 378.02% 8,846.22% -98.82%
EBIT Q/Q Growth		 -2.88% 18.97% 55.41% -15.54% 50.65% -38.61% 8.48% 135.18% 116.48% 141.77% -329.14%
NOPAT Q/Q Growth		 -1.69% 15.28% 59.68% -17.50% 44.12% -18.22% -22.93% 210.63% -9.68% 133.43% -232.55%
Net Income Q/Q Growth		 -13.69% 56.76% 24.25% -8.68% 53.03% 213.61% -171.27% 323.34% 88.83% -69.68% -397.91%
EPS Q/Q Growth		 -15.00% 53.85% 30.00% -9.09% 37.50% 214.29% -177.78% 325.00% 89.19% -68.18% -414.29%
Operating Cash Flow Q/Q Growth		 0.37% -18.11% 21.87% 51.77% -32.95% -5.38% 18.32% 2.99% 1.04% -37.69% 41.65%
Free Cash Flow Firm Q/Q Growth		 77.21% 154.79% -78.21% 4.85% -53.68% -20.64% -0.78% 30.36% 60.69% -35.65% 375.65%
Invested Capital Q/Q Growth		 -1.22% -1.08% 0.12% -0.42% 0.27% -0.03% -2.71% -0.17% -3.42% -1.64% -2.45%
Profitability Metrics		 - - - - - - - - - - -
EBITDA Margin		 54.78% 54.90% 54.12% 45.82% 52.26% 48.67% 58.12% 58.13% 52.13% 53.51% 0.72%
EBIT Margin		 25.88% 26.70% 23.60% 15.35% 19.20% 14.75% 23.98% 22.58% 9.69% 15.05% -43.13%
Profit (Net Income) Margin		 25.76% 29.90% 20.05% 16.32% 18.87% 12.66% -11.13% 15.95% -7.21% -61.96% -43.71%
Tax Burden Percent		 99.52% 98.99% 101.63% 98.53% 96.16% 93.19% 107.86% 95.58% 119.77% -2,431.95% 111.00%
Interest Burden Percent		 100.00% 113.11% 83.61% 107.87% 102.23% 92.14% -43.02% 73.89% -62.10% 16.93% 91.29%
Effective Tax Rate		 1.02% 0.81% -0.90% 1.80% 1.66% 2.68% 0.00% 1.47% 0.00% 3.55% 0.00%
Return on Invested Capital (ROIC)		 3.02% 2.97% 2.60% 1.59% 1.98% 1.37% 1.66% 2.06% 0.67% 0.70% -2.04%
ROIC Less NNEP Spread (ROIC-NNEP)		 3.03% 3.22% 2.37% 1.66% 1.95% 1.31% 0.08% 1.72% -0.13% -3.19% -2.76%
Return on Net Nonoperating Assets (RNNOA)		 2.69% 2.80% 2.04% 1.42% 1.65% 1.10% 0.06% 1.34% -0.10% -2.43% -2.17%
Return on Equity (ROE)		 5.70% 5.78% 4.64% 3.01% 3.63% 2.46% 1.72% 3.40% 0.57% -1.73% -4.22%
Cash Return on Invested Capital (CROIC)		 5.32% 3.52% 2.04% 4.79% 4.67% 8.01% 8.95% 7.90% 6.29% 4.28% 6.40%
Operating Return on Assets (OROA)		 2.97% 2.95% 2.50% 1.57% 1.91% 1.42% 2.30% 2.03% 0.87% 1.33% -3.10%
Return on Assets (ROA)		 2.95% 3.30% 2.13% 1.67% 1.88% 1.22% -1.07% 1.43% -0.64% -5.48% -3.14%
Return on Common Equity (ROCE)		 5.70% 5.78% 4.64% 3.01% 3.63% 2.46% 1.72% 3.40% 0.57% -1.73% -4.22%
Return on Equity Simple (ROE_SIMPLE)		 5.21% 0.00% 3.54% 1.89% 1.79% 0.00% -3.08% -4.19% -4.29% 0.00% -0.53%
Net Operating Profit after Tax (NOPAT)		 40 41 35 22 27 19 23 30 9.52 11 -32
NOPAT Margin		 25.62% 26.11% 23.81% 15.08% 19.30% 13.75% 16.79% 22.25% 7.23% 7.68% -27.51%
Net Nonoperating Expense Percent (NNEP)		 -0.01% -0.25% 0.23% -0.08% 0.02% 0.06% 1.58% 0.34% 0.80% 3.90% 0.72%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 74.23% 73.38% 76.50% 84.76% 80.90% 85.52% 75.78% 77.09% 90.46% 84.83% 143.32%
Earnings before Interest and Taxes (EBIT)		 40 42 35 23 27 20 33 30 13 21 -49
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 86 86 80 67 73 66 79 77 69 73 0.82
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.54 1.47 1.59 1.27 1.19 1.07 1.03 0.83 0.78 0.78 0.79
Price to Tangible Book Value (P/TBV)		 1.55 1.48 1.61 1.28 1.20 1.08 1.05 0.84 0.79 0.79 0.80
Price to Revenue (P/Rev)		 6.84 6.81 7.65 6.28 6.04 5.60 5.52 4.74 4.55 4.58 5.83
Price to Earnings (P/E)		 29.53 31.76 44.86 66.92 66.31 217.85 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 6.87% 7.06% 6.45% 7.94% 8.45% 9.26% 9.35% 11.35% 11.92% 11.69% 10.96%
Earnings Yield		 3.39% 3.15% 2.23% 1.49% 1.51% 0.46% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1.28 1.24 1.30 1.13 1.09 1.03 1.01 0.90 0.87 0.87 0.87
Enterprise Value to Revenue (EV/Rev)		 10.72 10.79 11.86 10.59 10.46 10.02 9.83 9.37 9.16 9.32 11.41
Enterprise Value to EBITDA (EV/EBITDA)		 20.47 20.83 23.85 20.94 19.46 18.46 26.39 39.63 40.99 20.74 29.36
Enterprise Value to EBIT (EV/EBIT)		 46.84 50.59 66.68 59.70 53.42 56.30 0.00 0.00 0.00 143.23 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 46.47 50.99 65.71 60.11 53.84 63.07 107.67 727.07 1,866.33 151.93 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 19.29 20.53 21.86 20.02 19.92 17.85 18.24 15.36 14.60 15.28 14.29
Enterprise Value to Free Cash Flow (EV/FCFF)		 23.73 34.89 63.68 23.30 22.92 12.43 10.85 10.96 13.43 19.89 13.22
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.89 0.88 0.90 0.89 0.89 0.86 0.82 0.82 0.81 0.82 0.76
Long-Term Debt to Equity		 0.86 0.84 0.84 0.84 0.84 0.83 0.81 0.79 0.78 0.76 0.72
Financial Leverage		 0.89 0.87 0.86 0.85 0.85 0.84 0.79 0.78 0.75 0.76 0.79
Leverage Ratio		 1.94 1.93 1.91 1.91 1.90 1.90 1.85 1.83 1.81 1.82 1.84
Compound Leverage Factor		 1.94 2.18 1.60 2.06 1.95 1.75 -0.79 1.36 -1.12 0.31 1.68
Debt to Total Capital		 46.97% 46.86% 47.37% 46.97% 47.10% 46.28% 45.02% 45.12% 44.61% 45.06% 43.27%
Short-Term Debt to Total Capital		 1.62% 2.07% 2.93% 2.50% 2.79% 1.81% 0.63% 1.87% 1.48% 3.54% 2.45%
Long-Term Debt to Total Capital		 45.35% 44.80% 44.44% 44.47% 44.30% 44.47% 44.40% 43.24% 43.13% 41.52% 40.82%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 53.03% 53.14% 52.63% 53.03% 52.90% 53.72% 54.98% 54.88% 55.39% 54.94% 56.73%
Debt to EBITDA		 7.51 7.90 8.72 8.68 8.44 8.31 11.75 19.84 20.97 10.78 14.53
Net Debt to EBITDA		 7.42 7.68 8.47 8.53 8.22 8.15 11.55 19.58 20.63 10.55 14.35
Long-Term Debt to EBITDA		 7.26 7.55 8.18 8.22 7.94 7.98 11.58 19.02 20.28 9.93 13.71
Debt to NOPAT		 17.06 19.34 24.01 24.91 23.35 28.38 47.92 364.07 954.75 78.95 -1,655.85
Net Debt to NOPAT		 16.85 18.81 23.34 24.48 22.73 27.83 47.13 359.20 939.34 77.26 -1,634.77
Long-Term Debt to NOPAT		 16.47 18.48 22.53 23.58 21.97 27.27 47.26 348.95 923.06 72.75 -1,562.09
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 175 98 39 177 169 365 460 464 356 221 344
Operating Cash Flow to CapEx		 1,031.26% 515.16% 706.12% 644.89% 408.16% 373.85% 322.56% 381.08% 349.48% 327.08% 757.74%
Free Cash Flow to Firm to Interest Expense		 6.44 3.51 1.31 6.05 5.95 13.07 16.34 16.37 12.46 7.94 12.71
Operating Cash Flow to Interest Expense		 2.96 2.85 3.31 2.73 1.86 2.82 2.96 2.48 2.39 2.42 4.01
Operating Cash Flow Less CapEx to Interest Expense		 2.67 2.29 2.84 2.31 1.40 2.06 2.04 1.83 1.71 1.68 3.48
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.11 0.11 0.11 0.10 0.10 0.10 0.10 0.09 0.09 0.09 0.07
Fixed Asset Turnover		 0.13 0.13 0.12 0.12 0.12 0.11 0.11 0.11 0.10 0.10 0.08
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 5,096 5,159 5,215 5,209 5,231 5,217 5,218 5,364 5,373 5,563 5,656
Invested Capital Turnover		 0.12 0.11 0.11 0.11 0.10 0.10 0.10 0.09 0.09 0.09 0.07
Increase / (Decrease) in Invested Capital		 -134 -58 -3.28 -155 -142 -347 -437 -434 -346 -211 -376
Enterprise Value (EV)		 6,521 6,375 6,761 5,903 5,680 5,364 5,279 4,833 4,685 4,824 4,944
Market Capitalization		 4,156 4,024 4,360 3,499 3,282 2,997 2,968 2,445 2,327 2,371 2,529
Book Value per Share		 $11.36 $11.59 $11.72 $11.93 $11.96 $12.12 $12.41 $12.73 $12.87 $13.23 $13.89
Tangible Book Value per Share		 $11.25 $11.47 $11.59 $11.81 $11.83 $11.99 $12.27 $12.58 $12.70 $13.06 $13.68
Total Capital		 5,096 5,159 5,215 5,209 5,231 5,217 5,218 5,364 5,373 5,563 5,656
Total Debt		 2,394 2,418 2,470 2,447 2,463 2,414 2,349 2,420 2,397 2,507 2,447
Total Long-Term Debt		 2,311 2,311 2,318 2,316 2,317 2,320 2,317 2,320 2,317 2,310 2,308
Net Debt		 2,365 2,351 2,401 2,404 2,397 2,367 2,311 2,388 2,358 2,453 2,416
Capital Expenditures (CapEx)		 7.78 16 14 12 13 21 26 18 20 21 14
Net Nonoperating Expense (NNE)		 -0.22 -5.92 5.58 -1.82 0.60 1.47 38 8.37 19 95 19
Net Nonoperating Obligations (NNO)		 2,394 2,418 2,470 2,447 2,463 2,414 2,349 2,420 2,397 2,507 2,447
Total Depreciation and Amortization (D&A)		 45 44 45 45 46 46 46 47 56 53 50
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.17 $0.20 $0.13 $0.10 $0.11 $0.08 ($0.07) $0.09 ($0.04) ($0.37) ($0.22)
Adjusted Weighted Average Basic Shares Outstanding		 237.89M 233.50M 234.29M 231.62M 231.45M 231.20M 231.22M 231.20M 231.16M 230.95M 230.98M
Adjusted Diluted Earnings per Share		 $0.17 $0.20 $0.13 $0.10 $0.11 $0.08 ($0.07) $0.09 ($0.04) ($0.37) ($0.22)
Adjusted Weighted Average Diluted Shares Outstanding		 240.30M 236.05M 237.04M 233.75M 233.37M 232.79M 231.22M 232.24M 231.16M 230.95M 230.98M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 237.94M 237.91M 236.59M 234.26M 231.50M 231.48M 231.22M 231.22M 231.20M 231.16M 230.98M
Normalized Net Operating Profit after Tax (NOPAT)		 99 100 65 91 84 73 57 78 49 64 43
Normalized NOPAT Margin		 63.53% 63.74% 44.09% 61.93% 60.11% 54.20% 41.97% 58.40% 36.87% 46.75% 37.92%
Pre Tax Income Margin		 25.88% 30.21% 19.73% 16.56% 19.63% 13.59% -10.32% 16.69% -6.02% 2.55% -39.37%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 1.49 1.49 1.19 0.77 0.94 0.72 1.16 1.06 0.45 0.74 -1.83
NOPAT to Interest Expense		 1.48 1.45 1.20 0.76 0.95 0.67 0.81 1.04 0.33 0.38 -1.16
EBIT Less CapEx to Interest Expense		 1.21 0.93 0.72 0.35 0.48 -0.04 0.24 0.41 -0.24 0.00 -2.35
NOPAT Less CapEx to Interest Expense		 1.19 0.90 0.73 0.33 0.49 -0.09 -0.11 0.39 -0.35 -0.36 -1.69
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 200.39% 221.09% 286.65% 531.00% 560.72% 2,016.92% -313.96% -224.88% -217.11% -357.14% -1,625.33%
Augmented Payout Ratio		 200.39% 153.13% 286.65% 531.00% 560.72% 2,016.92% -313.96% -224.88% -217.11% -357.14% -1,625.33%

Frequently Asked Questions About Sabra Health Care REIT's Financials

When does Sabra Health Care REIT's fiscal year end?

According to the most recent income statement we have on file, Sabra Health Care REIT's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Sabra Health Care REIT's net income changed over the last 9 years?

Sabra Health Care REIT's net income appears to be on a downward trend, with a most recent value of $126.71 million in 2024, rising from $79.38 million in 2015. The previous period was $13.76 million in 2023. View Sabra Health Care REIT's forecast to see where analysts expect Sabra Health Care REIT to go next.

How has Sabra Health Care REIT revenue changed over the last 9 years?

Over the last 9 years, Sabra Health Care REIT's total revenue changed from $240.96 million in 2015 to $590.70 million in 2024, a change of 145.1%.

How much debt does Sabra Health Care REIT have?

Sabra Health Care REIT's total liabilities were at $2.56 billion at the end of 2024, a 0.8% decrease from 2023, and a 81.1% increase since 2015.

How much cash does Sabra Health Care REIT have?

In the past 9 years, Sabra Health Care REIT's cash and equivalents has ranged from $7.43 million in 2015 to $518.63 million in 2017, and is currently $60.47 million as of their latest financial filing in 2024.

How has Sabra Health Care REIT's book value per share changed over the last 9 years?

Over the last 9 years, Sabra Health Care REIT's book value per share changed from 16.18 in 2015 to 11.59 in 2024, a change of -28.4%.


Related Companies

This page (NASDAQ:SBRA) was last updated on 5/31/2025 by MarketBeat.com Staff
From Our Partners
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsored
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...
Colonial Metals | Sponsored
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...
Porter & Company | Sponsored
Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...
Stansberry Research | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...
Paradigm Press | Sponsored